{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-302915","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2022-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.105587+00:00","generated_at":"2026-06-21T05:23:28.285610+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nurix reports positive Phase 1 data for BTK degrader NX-2127; 33% ORR in heavily pretreated CLL","bullets":["ORR of 33% (95% CI 12-62%) in 23 CLL patients who failed median 5 prior therapies, 78% prior BTK+BCL2 inhibitors.","48% of CLL patients had BTK resistance mutations; NX-2127 showed activity regardless of mutational status.","Median follow-up 5.6 months; 14 of 23 CLL patients remained on treatment as of Sept 21, 2022 data cut.","BTK mutations resistant to covalent and non-covalent inhibitors remained susceptible to degradation by NX-2127.","Safety profile consistent with prior Phase 1a results and BTK-targeted therapies in heavily pretreated patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-302915","json":"https://secwatch.observer/filing/0001193125-22-302915.json","markdown":"https://secwatch.observer/filing/0001193125-22-302915.md","text":"https://secwatch.observer/filing/0001193125-22-302915.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522302915/0001193125-22-302915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000119312522302915/d411325d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T05:23:28.285610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}